Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We investigated whether progranulin plasma levels are predictors of the presence of progranulin gene (GRN) null mutations or of the development of symptoms in asymptomatic at risk members participating in the Genetic Frontotemporal Dementia Initiative, including 19 patients, 64 asymptomatic carriers, and 77 noncarriers. In addition, we evaluated a possible role of TMEM106B rs1990622 as a genetic modifier and correlated progranulin plasma levels and gray-matter atrophy. Plasma progranulin mean ± SD plasma levels in patients and asymptomatic carriers were significantly decreased compared with noncarriers (30.5 ± 13.0 and 27.7 ± 7.5 versus 99.6 ± 24.8 ng/mL, p < 0.00001). Considering the threshold of >61.55 ng/mL, the test had a sensitivity of 98.8% and a specificity of 97.5% in predicting the presence of a mutation, independent of symptoms. No correlations were found between progranulin plasma levels and age, years from average age at onset in each family, or TMEM106B rs1990622 genotype (p > 0.05). Plasma progranulin levels did not correlate with brain atrophy. Plasma progranulin levels predict the presence of GRN null mutations independent of proximity to symptoms and brain atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationTMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
Finch, N., Carrasquillo, M. M., Baker, M., Rutherford, N. J., Coppola, G., DeJesus-Hernandez, M., Crook, R., Hunter, T., Ghidoni, R., Benussi, L., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0e3b · Cited by 243 · cited 4×
“This gene has been actually demonstrated to act as a genetic modi fi er of GRN mutations, in fl uencing the age at disease onset and progranulin levels in mutation carriers (Cruchaga et al., 2011; Finch et al., 2011).”
InfluentialSelf-citation
Cited by
An update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Self-citationNeuroinflammation in frontotemporal dementia
Bright, F., Werry, E. L., Dobson-Stone, C., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kassiou, M., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0231-z · Cited by 280
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182
Self-citationHomozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms
Huin, V., Barbier, M., Bottani, A., Lobrinus, J. A., Clot, F., Lamari, F., Chat, L., Rucheton, B., Fluchère, F., Auvin, S., et al. (2020) · Brain · doi:10.1093/brain/awz377 · Cited by 96
“lin levels are highly predictive of pathogenic heterozygous GRN mutations. Different thresholds of 110 (Finch et al., 2009), 74 (Ghidoni et al., 2008), or more recently 61 mg/l (Ghidoni et al., 2012; Galimberti et al., 2018) have been established depending on the study. All heterozygous GRN mutations are associated wi…”
BackgroundMicroglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8030230 · Cited by 72
“Others have suggested that serum/plasma PGRN levels can have disease diagnostic value for undiagnosed and presymptomatic FTLD [89].”
Background
Metadata
- Authors
- Galimberti, D., Fumagalli, G. G., Fenoglio, C., Cioffi, S. M. G., Arighi, A., Serpente, M., Borroni, B., Padovani, A., Tagliavini, F., Masellis, M., Tartaglia, M. C., van Swieten, J., Meeter, L., Graff, C., de Mendonça, A., Bocchetta, M., Rohrer, J. D., Scarpini, E., Andersson, C., Archetti, S., Arighi, A., Benussi, L., Binetti, G., Black, S., Cash, D., Cosseddu, M., Dick, K. M., Fallström, M., Ferreira, C., Finger, E., Fox, N., Freedman, M., Frisoni, G., Gazzina, S., Ghidoni, R., Grisoli, M., Jelic, V., Jiskoot, L., Keren, R., Laforce, R., Lombardi, G., Maruta, C., Mead, S., Meeter, L., van Minkelen, R., Nacmias, B., Öijerstedt, L., Ourselin, S., Panman, J., Pievani, M., Polito, C., Prioni, S., Rademakers, R., Redaelli, V., Rogaeva, E., Rossi, G., Besta, C., Rossor, M., Rowe, J., Sorbi, S., Tang-Wai, D., Thomas, D. L., Thonberg, H., Tiraboschi, P., Verdelho, A., & Warren, J.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 62
- Pages
- 245.e9-245.e12
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2770087407
- Cited by
- 58
- References
- 2
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2017.10.016
- The paper
- Galimberti, D., Fumagalli, G. G., Fenoglio, C., Cioffi, S. M. G., Arighi, A., Serpente, M., Borroni, B., Padovani, A., Tagliavini, F., Masellis, M., Tartaglia, M. C., van Swieten, J., Meeter, L., Graff, C., de Mendonça, A., Bocchetta, M., Rohrer, J. D., Scarpini, E., Andersson, C., . . . Warren, J. (2018). Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2017.10.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.